Grail reports Q3 EPS ($2.46) vs. ($3.05) last year

Reports Q 3revenue $36.2M, consensus $35.4M. Cash, cash equivalents, restricted cash and short-term marketable securities of $547.1M as of September 30 provide runway into 2030. “We remain very pleased by Galleri’s commercial uptake with 39% growth in Galleri test volume in Q3. Our teams continue to build awareness of Galleri among providers and patients, and recent data from our registrational PATHFINDER 2 study adds to the evidence base,” said CEO Bob Ragusa. “We have also made key recent strides in opportunities beyond the U.S., led by our strategic collaboration with Samsung to bring Galleri to key Asian markets, as well as Galleri’s commercial introduction in Canada. Looking ahead, we anticipate completing our PMA submission for Galleri to the FDA in Q1 2026.”